CANTOR SING is a pilot single center double blinded randomized study. The investigators will
compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control
group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial
infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients
in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic
uptake between baseline and 6 months in each arm.